Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,036 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.
Najima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. Najima Y, et al. Among authors: igarashi t. Leuk Res. 2018 Mar;66:66-72. doi: 10.1016/j.leukres.2018.01.010. Epub 2018 Feb 3. Leuk Res. 2018. PMID: 29407585 Clinical Trial.
Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group.
Yamaguchi H, Takezako N, Ohashi K, Oba K, Kumagai T, Kozai Y, Wakita H, Yamamoto K, Fujita A, Igarashi T, Yoshida C, Ohyashiki K, Okamoto S, Sakamoto J, Sakamaki H, Inokuchi K. Yamaguchi H, et al. Among authors: igarashi t. Int J Hematol. 2020 Mar;111(3):401-408. doi: 10.1007/s12185-019-02801-z. Epub 2020 Jan 1. Int J Hematol. 2020. PMID: 31894533
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Iriyama N, et al. Among authors: igarashi t. Am J Hematol. 2015 Apr;90(4):282-7. doi: 10.1002/ajh.23923. Epub 2015 Mar 2. Am J Hematol. 2015. PMID: 25530131 Free article. Clinical Trial.
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Iriyama N, et al. Among authors: igarashi t. Am J Hematol. 2015 Sep;90(9):819-24. doi: 10.1002/ajh.24096. Am J Hematol. 2015. PMID: 26103598 Free article. Clinical Trial.
Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
Hagihara M, Iriyama N, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Hagihara M, et al. Among authors: igarashi t. Oncol Rep. 2016 Nov;36(5):2976-2982. doi: 10.3892/or.2016.5110. Epub 2016 Sep 20. Oncol Rep. 2016. PMID: 27665844 Clinical Trial.
Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5 ): The phase 2, multicenter N-Road study.
Nishiwaki K, Sugimoto KJ, Tamaki S, Hisatake J, Yokoyama H, Igarashi T, Shinagawa A, Sugawara T, Hara S, Fujikawa K, Shimizu S, Yujiri T, Tojo A, Wakita H. Nishiwaki K, et al. Among authors: igarashi t. Cancer Med. 2020 Jun;9(11):3742-3751. doi: 10.1002/cam4.3034. Epub 2020 Apr 6. Cancer Med. 2020. PMID: 32253827 Free PMC article. Clinical Trial.
Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response.
Okamoto Y, Hirano M, Morino K, Kajita MK, Nakaoka S, Tsuda M, Sugimoto KJ, Tamaki S, Hisatake J, Yokoyama H, Igarashi T, Shinagawa A, Sugawara T, Hara S, Fujikawa K, Shimizu S, Yujiri T, Wakita H, Nishiwaki K, Tojo A, Aihara K. Okamoto Y, et al. Among authors: igarashi t. NPJ Syst Biol Appl. 2022 Oct 13;8(1):39. doi: 10.1038/s41540-022-00248-3. NPJ Syst Biol Appl. 2022. PMID: 36229495 Free PMC article.
Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
Noguchi S, Nakaseko C, Nishiwaki K, Ogasawara H, Ohishi K, Tokuhira M, Noguchi M, Kimura H, Handa H, Mitani K, Miura M, Wakita H, Takahashi N; STAT study group. Noguchi S, et al. Int J Hematol. 2018 Aug;108(2):176-183. doi: 10.1007/s12185-018-2459-6. Epub 2018 Apr 30. Int J Hematol. 2018. PMID: 29713954 Clinical Trial.
2,036 results